|
Groups
|
IL-1
|
TNF-α
|
VEGF
|
bFGF
|
MCP-1
|
|---|
|
Normal controls
|
0.23 ± 0.20
|
0.13 ± 0.07
|
1.39 ± 0.01
|
0.41 ± 0.18
|
0.26 ± 0.14
|
|
AIA controls
|
1.40 ± 0.29*
|
1.19 ± 0.19*
|
3.40 ± 1.05*
|
5.24 ± 0.35*
|
1.05 ± 0.18*
|
|
AIA + ROSI 10
|
0.98 ± 0.06
|
1.39 ± 0.16
|
3.79 ± 0.28
|
4.59 ± 0.77
|
1.51 ± 0.22
|
|
AIA + PIO 30
|
0.66 ± 0.16#
|
0.37 ± 0.11#
|
4.67 ± 0.21
|
2.18 ± 0.61#
|
1.51 ± 0.21
|
- PPAR, peroxisome proliferator-activated receptor; AIA, adjuvant-induced arthritis; ROSI 10, rosiglitazone 10 mg/kg/day; PIO 30, pioglitazone 30 mg/kg/day; VEGF, vascular endothelial growth factor; bFGF, basic fibroblast growth factor; MCP-1, monocyte chemotactic protein-1. Data are expressed as means ± SEM of mRNAs of the gene of interest over L27 mRNA (n = 3 representative samples per group).
- *, P < 0.05 compared with normal controls; #, P < 0.05 compared with AIA controls (ANOVA and Fisher's PLSD test).
